This dual-targeting shows promising antileukemic effects in AML cell lines and primary blasts with the FLT3-ITD mutation, downregulating adipogenesis, fatty acid metabolism, and IL6/JAK/STAT3 and PI3K/AKT/MTOR pathways [101]. The gene discussed is FLT3; the disease is acute myeloid leukemia.